Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®)

Eur Arch Otorhinolaryngol. 2012 Feb;269(2):361-2. doi: 10.1007/s00405-011-1804-7. Epub 2011 Oct 22.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects*
  • Cidofovir
  • Cytosine / administration & dosage
  • Cytosine / adverse effects
  • Cytosine / analogs & derivatives*
  • Injections, Intralesional
  • Neoplasms / chemically induced
  • Neutropenia / chemically induced
  • Off-Label Use*
  • Organophosphonates / administration & dosage
  • Organophosphonates / adverse effects*
  • Papilloma / drug therapy*
  • Papillomavirus Infections / drug therapy*
  • Recurrence
  • Renal Insufficiency / chemically induced
  • Respiratory Tract Infections / drug therapy*

Substances

  • Antiviral Agents
  • Organophosphonates
  • Cytosine
  • Cidofovir

Supplementary concepts

  • Recurrent respiratory papillomatosis